雷珠单抗治疗视网膜静脉阻塞合并黄斑水肿的时机及疗效观察

冰 高(承德医学院附属医院，中国)
畅 苏(承德医学院附属医院，中国)
锐锋 苏(承德医学院附属医院，中国)

摘要

目的：探讨雷珠单抗治疗视网膜静脉阻塞（RV O）合并黄斑水肿（ME）的时机及疗效。方法：回顾性临床研究。选取我院2022-03至2023-06收治的RV O继发ME患者60例（60眼），按RV O发病至第一次玻璃体腔注药时间平均分为三组，A组≤1个月，B组1~2个月，C组≥2个月。随访至少6个月，观察BCVA、CMT、6个月内注射次数。结果：最终A组与B组BCVA比较无差异，B组优于C组。CMT组内比较，治疗后三组较前均下降；A组、B组在3mo和6mo时比较无差异；C组6mo时较3mo时薄。组间比较，1mo和3mo时，A组与B组比较差异无意义，B组较C组薄。注射次数比较，A组与B组比较无差异，B组少于C组。结论：对于RV O继发ME患者，早期进行抗VEGF药物注射ME消退更快、恢复更好、次数更少。

关键词

视网膜静脉阻塞；黄斑水肿；雷珠单抗

参考

Moon BG, ChoAR, Kim YN, et al. Predictors of refractory macular edema after branch retinal vein occlusion following intravitreal bevacizumab. Retina, 2018,38(6):1166-1174.

Thapa R, Bajimaya S, Paudyal G, et al. Prevalence,pattern and risk factors of retinal vein occlusion in an elderly population in Nepal: the Bhaktapur retina study. BMC Ophthalmol, 2017,17(1):162.

秦书艳,沈磊,力强.玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿[J].国际眼科杂志,2016,16(12):2329-2331.

赵明亮,陈翀,张超,等.基于脑血管重建的血管内皮生长因子缓释微球制备及性质研究[J].新乡医学院学报,2015,32(3):205-208.

王雪飞,覃东菊,李明哲,等.玻璃体内注射雷珠单抗联合577nm激光治疗视网膜静脉阻塞合并黄斑水肿的疗效观察[J].国际眼科杂志,2017(12):147-149.

杨杰,彭南祥,陈季生.玻璃体腔注射不同药物联合激光治疗视网膜静脉阻塞合并黄斑水肿的疗效比较[J].国际眼科杂志,2017,17(10):1912-1914.

Noma H,Funatsu H,Mimura T,et al. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular edema and central retinal vein occlusion. Acta Ophthalmol, 2010;88(6):646-651.

葛坚.眼科学[M].北京:人民卫生出版社,2005.

徐娜,高荣玉,徐鑫彦,等.玻璃体腔注射康柏西普对视网膜分支静脉阻塞引发的不同类型黄斑水肿的疗效[J].中华实验眼科杂志,2018,36(8):619-624.

张楠,吴烈,桑子瑾.RVO伴发新生血管性眼病的发病机制及治疗进展[J].中国中医眼科杂志,2012,22(6):450-455.

Singh D, Roche N, Halpin D, et al. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2016,194(5):541-549.

Tsagkataki M, Papathomas T, Lythgoe D, et al. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. Semin Ophthalmol, 2015,30(5-6):352-359.

Minami Y, Nagaoka T, Ishibazawa A, et al. Correlation between short and long term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study. BMC Ophthalmol, 2017,17(1):90.

Rezar S, Eibenberger K, Bühl, Wolf, et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years[J]. Acta Ophthalmologica, 2015, 93(8):719-725.

JOSEPH P, OTZEM C, YUMNA B, et al. Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome[J]. Journal of Ophthalmology, 2013, 2013:974670.

WAI KM, KHAN M, SRIVASTAVA S, et al. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice[J]. Br J Ophthalmol, 2017,101(5):574-579.

许冬,周利晓,关丽珂.视网膜静脉阻塞伴黄斑水肿抗VEGF治疗预后影响因素研究[J].中国现代医药杂志,2019,21(11):1-3.

BROGAN K, PRECUP M, RODER A, et al. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab[J]. BMC Ophthalmol, 2018,18(1):37.

薛灿灿,窦宏亮.影响视网膜中央静脉阻塞黄斑水肿视力预后的主要因素[J].中华眼底病杂志,2018,v.34(03):291-295.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i12.22863